FBW7/GSK3β mediated degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback loop and radioresistance in lung cancer

Zhiyuan Zhou, Bin Zhang, Yue Deng, Suke Deng, Jie Li, Wenwen Wei, Yijun Wang, Jiacheng Wang, Zishan Feng, Mengjie Che, Yang Xiao, Jingshu Meng, Yan Li, Yan Hu, Yajie Sun, Lu Wen, Fang Huang, Yuhan Sheng, Chao Wan, Kunyu YangJournal of Experimental & Clinical Cancer Research 2024 · DOI

Abstract

Collectively, our study revealed that the m<sup>6</sup>A "reader" IGF2BP2 promotes lung cancer radioresistance by forming a positive feedback loop with SLC7A5, suggesting that IGF2BP2 may be a potential therapeutic target to control radioresistance in lung cancer.

Introduction: The Challenge of Radioresistance

Radiotherapy is a primary treatment modality for non-small cell lung cancer (NSCLC). However, the development of radioresistance often leads to treatment failure and tumor recurrence. While $N^6$-methyladenosine ($m^6A$) RNA modification is known to regulate cancer progression, its specific role in radioresistance has remained largely unexplored. This study identifies the $m^6A$ "reader" IGF2BP2 as a critical driver of radioresistance in lung cancer through a self-reinforcing metabolic and epigenetic feedback loop.

Methods and Data Sources

The researchers utilized a comprehensive approach to map the mechanisms of resistance:

  • Bioinformatics & Clinical Data: Analysis of TCGA-LUAD datasets and tissue microarrays correlated IGF2BP2 expression with patient outcomes.
  • Molecular Assays: RIP-qPCR, MeRIP-qPCR, and ChIP-qPCR were used to define the interactions between IGF2BP2, $m^6A$ sites, and gene promoters.
  • Functional Radiobiology: Clonogenic survival assays and neutral comet assays quantified cellular survival and DNA damage following radiation.
  • In Vivo Validation: Subcutaneous xenograft mouse models were employed to test the efficacy of targeting the IGF2BP2 pathway in combination with radiotherapy.

The IGF2BP2-SLC7A5 Feedback Loop

The study uncovered a sophisticated "vicious cycle" that sustains radioresistance:

  1. RNA Stabilization: IGF2BP2 binds to and stabilizes the mRNA of the amino acid transporter SLC7A5.
  2. Metabolic Reprogramming: Increased SLC7A5 levels lead to higher Methionine uptake.
  3. Epigenetic Activation: Methionine is converted to SAM, facilitating H3K4me3 histone modification at the IGF2BP2 promoter, which further increases its expression.
  4. Pathway Activation: This loop activates the AKT/mTOR signaling pathway, enhancing the cell's ability to repair radiation-induced DNA damage.

Key Results: Sensitizing Resistant Tumors

The researchers demonstrated that disrupting this loop significantly enhances radiation sensitivity.

IGF2BP2 expression correlates with poor survival and promotes radioresistance in lung cancer models.
  • Clinical Impact: High IGF2BP2 expression is a negative prognostic factor in lung cancer patients, as shown in TCGA survival analysis (Fig. 1D).
  • DNA Damage Visualization: Knocking down IGF2BP2 (shBP2#1/2) resulted in significantly increased DNA strand breaks after radiation, as evidenced by longer "comet tails" in neutral comet assays.
Neutral comet assays show increased DNA damage (longer tails) in IGF2BP2-depleted cells following radiation.
  • In Vivo Efficacy: In mouse models, silencing IGF2BP2 combined with radiation (IR) led to a dramatic reduction in tumor volume and mass compared to radiation alone (Fig. 1L).
  • Regulatory Control: The study identified the FBW7/GSK3β axis as a natural regulator that degrades IGF2BP2, providing a blueprint for potential therapeutic intervention.

Conclusion and Future Directions

This research highlights IGF2BP2 as a pivotal regulator of radioresistance and a promising therapeutic target. While the mechanism is well-defined, future work is needed to develop clinical-grade inhibitors or PROTACs that can effectively target IGF2BP2. Understanding the full spectrum of ubiquitin ligases involved in this pathway will also be crucial for optimizing treatment strategies to overcome resistance in NSCLC patients.

Summary updated

Abstract

Collectively, our study revealed that the m<sup>6</sup>A "reader" IGF2BP2 promotes lung cancer radioresistance by forming a positive feedback loop with SLC7A5, suggesting that IGF2BP2 may be a potential therapeutic target to control radioresistance in lung cancer.
BibTeX
@article{zhou2024fbw,
  author = {Zhiyuan Zhou and Bin Zhang and Yue Deng and Suke Deng and Jie Li and Wenwen Wei and Yijun Wang and Jiacheng Wang and Zishan Feng and Mengjie Che and Yang Xiao and Jingshu Meng and Yan Li and Yan Hu and Yajie Sun and Lu Wen and Fang Huang and Yuhan Sheng and Chao Wan and Kunyu Yang},
  title = {{FBW7/GSK3β mediated degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback loop and radioresistance in lung cancer}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2024},
  doi = {10.1186/s13046-024-02959-3},
}
Figure